NCT01525017View on ClinicalTrials.gov

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Metastatic Renal Cell Carcinoma
Interventions
BIOLOGICAL

Combig-DC (allogeneic dendritic cells) Cancer Vaccine

Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).

Trial Locations (1)

751 85

Dept of Oncology, University Hospital, Uppsala

Sponsors

Lead Sponsor

Mendus
All Listed Sponsors
lead

Mendus

INDUSTRY

NCT01525017 - A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter